Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Neurocrine Biosciences Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.59, while Neurocrine Biosciences Inc trades at $171.33 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | NBIX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $180.55 |
52-Week Low | $91.59 | $123.10 |
Market Cap | — | $17.30B |
Enterprise Value | — | $16.39B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
